Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 271 followers
Latest posts
Last updated about 2 months ago
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
about 2 months ago
Adults taking Foundayo lost an average of 27 pounds on the highest...
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
about 2 months ago
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise...
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
about 2 months ago
Taltz and Zepbound used together provided comprehensive improvements in disease activity and...
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
about 2 months ago
In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful...
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
2 months ago
For the primary endpoint, retatrutide lowered A1C by an average of 1.7%...
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect
2 months ago
Today, Eli Lilly and Company announced that access to self-pay pricing on...
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
2 months ago
In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin...
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12
2 months ago
Lilly is issuing a public warning about potential safety risks associated with...
Lilly’s statement on the CMMI BALANCE Model for GLP-1 medicines
3 months ago
Today, the Centers for Medicare and Medicaid Services issued new implementation details...
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
3 months ago
Zepbound ® (tirzepatide) KwikPen ® for single-patient use available from Lilly at...
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
3 months ago
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS...
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
3 months ago
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs...